IGF2BP1 and neoplasm: This was evaluated for selected oncogenes/tumor suppressors (control) and essential genes located at Chr 17q by integrating: i) gene dependency score in MNA neuroblastoma cell lines, ii) fold change of mRNA in 17q unbalanced, MNA or INSS-4 tumors, iii) gene hazardous ratio, iv) correlation of mRNA expression with MYCN and IGF2BP1 in tumors, v) fold change of mRNA upon MYCN or IGF2BP1 depletion, vi) MYCN ChIP-seq data, vii) IGF2BP1-CLIP data (Supplementary Fig. 8a; Supplementary Tables 2, 4, 5, and 9).